SB 369 (Louisiana) creates a single benchmark for prescription drugs sold to state-sponsored plans by prohibiting pharmaceutical manufacturers from offering any drug to an Office of Group Benefits plan or any other state-sponsored insurance plan at a price higher than the price Medicare pays for that drug. It also bars insurers, pharmacy benefit managers (PBMs), and agents of PBMs from reimbursing for brand-name drugs, biosimilars, or generics at amounts below the Medicare price.
The bill tasks the insurance commissioner with enforcement and rulemaking and takes effect January 1, 2027.
This is materially significant for manufacturers, PBMs, and state plan administrators because it replaces negotiated, confidential pricing practices with a statutory Medicare benchmark. If implemented as written, the bill will change contracting dynamics, data and compliance requirements, and could trigger market responses — from reformulated rebate structures to potential supply or access decisions by manufacturers — all of which agencies and private payers will need to anticipate and manage.
At a Glance
What It Does
The bill sets a statutory ceiling on what manufacturers may offer state-sponsored plans and a statutory floor on what insurers and PBMs may reimburse, both tied to 'the price Medicare pays' for the same drug. It delegates enforcement and the authority to promulgate implementing rules to the insurance commissioner.
Who It Affects
Directly affects pharmaceutical manufacturers that sell into Louisiana state-sponsored plans (including the Office of Group Benefits), private insurers and PBMs that reimburse drugs in Louisiana, and the Louisiana Insurance Department charged with enforcement. Indirectly affects pharmacies, beneficiaries of state plans, and manufacturers' broader pricing strategies.
Why It Matters
The measure replaces negotiated pricing for state plans with a Medicare-based benchmark, potentially compressing margins, exposing gaps where Medicare pricing is inapplicable or confidential, and raising preemption and implementation questions for self-insured ERISA plans and private payers. Compliance will require new data mapping and operational processes.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
SB 369 creates a clear, binary pricing rule: manufacturers may not offer drugs to Louisiana state-sponsored plans at a price above what Medicare pays, and insurers/PBMs may not reimburse drugs below the Medicare price. The statute names the Office of Group Benefits (OGB) explicitly as a covered plan example and covers brand-name drugs, biosimilars, and generics in the reimbursement prohibition.
The text is short and leaves many operational details to administrative rulemaking.
Practically, the statute forces market participants to identify a single Medicare price for each product and align offers and reimbursements to that figure. That will require insurers and PBMs to map their formularies and reimbursement schedules to Medicare benchmarks, determine whether Medicare Part B, Part D, or another Medicare pricing metric applies, and develop systems to calculate per-prescription payments consistent with the law.
Manufacturers that historically set list prices or negotiated confidential net prices will need to decide whether to lower offers to match Medicare, alter rebate contracts, or restrict distribution to certain plans.The insurance commissioner is assigned enforcement authority and rulemaking power, which means the department will define the missing mechanics: which Medicare price counts, how to handle situations where Medicare does not pay (e.g., certain oral drugs under Part B, or drugs covered under different Medicare programs), whether Medicare’s net prices or list prices are the benchmark, and what remedies or penalties apply for violations. Because the statute does not specify remedies, affected parties should expect the department’s rulemaking to determine compliance timelines, reporting requirements, and penalties.Two structural gaps are immediate: first, the bill applies to 'insurer' and 'PBM' reimbursement decisions broadly but does not address whether state regulation can reach self-insured employer plans governed by ERISA; second, the text does not define 'price Medicare pays,' leaving room for substantial interpretive work about which Medicare program, whether negotiated or administrative prices, and whether rebates and discounts factor into the benchmark.
Those points will shape both legal exposure and real-world impacts on patient access and payer costs.
The Five Things You Need to Know
SB 369 adds R.S. 22:1867.1, which prohibits a pharmaceutical manufacturer from offering any drug to an Office of Group Benefits plan or any state-sponsored insurance plan at a price greater than the price Medicare pays for that drug.
The bill forbids insurers, pharmacy benefit managers, or persons acting for PBMs from providing reimbursement for name-brand drugs, biosimilars, or generics at amounts lower than the price Medicare pays for the same drug.
Enforcement and rulemaking authority is assigned to 'the commissioner' under the statute, creating an administrative route for implementing technical definitions and compliance processes.
The statute goes into effect January 1, 2027, creating a finite lead time for covered entities to develop benchmarking and compliance systems tied to Medicare pricing.
The text does not define 'price Medicare pays' or explain whether Medicare list, net, or program-specific prices (Part B vs. Part D) are the applicable benchmark, leaving a central operational ambiguity to administrative rules.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Manufacturer price cap for state-sponsored plans
This subsection prohibits a pharmaceutical manufacturer from offering any drug to an Office of Group Benefits plan or any other state-sponsored insurance plan at a price higher than the price Medicare pays for the same drug. Operationally, manufacturers will need to track which of their products are supplied to state plans and ensure their offered prices do not exceed the relevant Medicare benchmark. The provision creates an explicit statutory constraint on manufacturer offers to state plans, but it does not specify delivery, reporting, or remedy mechanisms — all of which the insurance department must later articulate.
Reimbursement floor for insurers and PBMs
This subsection requires insurers, PBMs, and agents acting for PBMs to refrain from reimbursing for brand-name, biosimilar, or generic drugs at amounts below the Medicare price. That shifts part of the compliance burden onto payers: they must determine the Medicare benchmark for each reimbursed product and ensure contract terms, formularies, and claims-processing systems enforce a reimbursement floor. The rule could interact awkwardly with existing network contracts, tiered copays, and rebate-dependent formularies, meaning payers will need to change claims adjudication and contract language to avoid under-reimbursement under the statute.
Enforcement and rulemaking assigned to the insurance commissioner
The commissioner—under Louisiana insurance law, the Insurance Commissioner—receives authority to enforce the statute and promulgate rules necessary to implement it. Since the statute itself leaves key terms undefined, the department’s forthcoming regulations will determine how to measure Medicare prices, what records entities must keep, audit authority, timelines for compliance, and any penalties. The practical effect of enforcement authority will depend heavily on the specifics the commissioner adopts and how aggressively the department uses civil enforcement tools.
Effective date
The act becomes effective January 1, 2027, giving covered manufacturers, insurers, PBMs, and the insurance department a defined countdown to operationalize benchmark calculations and compliance programs. That timeline creates pressure on the department to issue guidance and on private parties to rework contracts and systems before the effective date.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Louisiana Office of Group Benefits and other state-sponsored plans — The bill explicitly protects state plans from being charged above the Medicare benchmark, which should constrain outlays if implemented as written.
- State plan members (employees and beneficiaries) — If the benchmark reduces gross prices paid by plans, state employees and retirees could see lower plan costs that translate into preserved benefits or lower contributions.
- Taxpayers and the state budget — By capping what manufacturers may charge state plans, the state could reduce public sector drug spending pressure, improving budget predictability.
Who Bears the Cost
- Pharmaceutical manufacturers — They may have to lower offers or restructure contracts and rebate strategies for state business, potentially reducing revenues on state accounts or changing distribution practices.
- Insurers and PBMs operating in Louisiana — They must build systems to identify, track, and enforce Medicare-based reimbursement floors and will likely incur compliance, IT, and contract-redrafting costs.
- Louisiana Insurance Department — The department will need to draft detailed rules, execute enforcement, and manage complaints without the statute specifying resources or penalties, imposing administrative burdens and possible needs for additional funding.
Key Issues
The Core Tension
The bill pits two legitimate aims against each other: the desire to constrain drug costs for publicly funded plans by anchoring payments to Medicare, and the practical/legal reality that a single Medicare benchmark is neither uniform across drugs nor easily mapped onto private contracting and rebate-driven markets—so enforcing the benchmark could lower public spend but also distort supply, contractual incentives, and raise preemption and implementation conflicts.
The statute rests on a deceptively simple hinge: 'the price Medicare pays.' That phrase is central, but Medicare covers drugs under multiple programs with different pricing methodologies (Part B administration-based reimbursement, Part D negotiated formulary pricing, 340B program pricing, and separate buy-and-bill arrangements). The bill does not identify which program’s price applies when the same molecule is covered differently in Medicare, nor does it say whether the benchmark is list price, net price after rebates, or a program-specific administrative rate.
The insurance department’s rules will therefore determine whether the benchmark is operationally useful or legally contestable.
Legal and market frictions are likely. The statute sweeps broadly at payers and PBMs but may bump against federal ERISA preemption for self-insured employer plans and other federal limits on state regulation of health benefits.
Manufacturers could respond by refusing to offer certain products to state plans, shifting supply, or altering rebate arrangements that underpin formularies, which could reduce access or change patient cost-sharing in unpredictable ways. Finally, enforcement without defined remedies creates uncertainty: the department could rely on cease-and-desist orders, fines, or contract review, but the absence of statutory penalties and recordkeeping requirements leaves compliance standards in flux until rules appear.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.